Mucosal vaccines for SARS-CoV-2: triumph of hope over experience
D Pilapitiya, AK Wheatley, HX Tan - EBioMedicine, 2023 - thelancet.com
Currently approved COVID-19 vaccines administered parenterally induce robust systemic
humoral and cellular responses. While highly effective against severe disease, there is …
humoral and cellular responses. While highly effective against severe disease, there is …
Intranasal vaccine: Factors to consider in research and development
H Xu, L Cai, S Hufnagel, Z Cui - International journal of pharmaceutics, 2021 - Elsevier
Most existing vaccines for human use are administered by needle-based injection.
Administering vaccines needle-free intranasally has numerous advantages over by needle …
Administering vaccines needle-free intranasally has numerous advantages over by needle …
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models
N van Doremalen, JN Purushotham… - Science translational …, 2021 - science.org
ChAdOx1 nCoV-19/AZD1222 is an approved adenovirus-based vaccine for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being deployed globally …
respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being deployed globally …
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses
H Ishii, T Nomura, H Yamamoto, M Nishizawa… - Cell Reports …, 2022 - cell.com
Effective vaccines are essential for the control of the coronavirus disease 2019 (COVID-19)
pandemic. Currently developed vaccines inducing severe acute respiratory syndrome …
pandemic. Currently developed vaccines inducing severe acute respiratory syndrome …
SARS-CoV-2 vaccines: where are we now?
The best and safest way to control the coronavirus disease 2019 (COVID-19) pandemic is by
using vaccination to generate widespread immunity. The urgent need to develop safe and …
using vaccination to generate widespread immunity. The urgent need to develop safe and …